[go: up one dir, main page]

DE69730352D1 - Verfahren zur herstellung eines arzneimittelkomplexes - Google Patents

Verfahren zur herstellung eines arzneimittelkomplexes

Info

Publication number
DE69730352D1
DE69730352D1 DE69730352T DE69730352T DE69730352D1 DE 69730352 D1 DE69730352 D1 DE 69730352D1 DE 69730352 T DE69730352 T DE 69730352T DE 69730352 T DE69730352 T DE 69730352T DE 69730352 D1 DE69730352 D1 DE 69730352D1
Authority
DE
Germany
Prior art keywords
spacer
drug compound
bound
carboxyl groups
polysaccharide derivative
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69730352T
Other languages
English (en)
Other versions
DE69730352T2 (de
Inventor
Kazuhiro Inoue
Hiroshi Susaki
Masahiro Ikeda
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Daiichi Pharmaceutical Co Ltd
Original Assignee
Daiichi Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Daiichi Pharmaceutical Co Ltd filed Critical Daiichi Pharmaceutical Co Ltd
Application granted granted Critical
Publication of DE69730352D1 publication Critical patent/DE69730352D1/de
Publication of DE69730352T2 publication Critical patent/DE69730352T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
DE69730352T 1996-06-06 1997-06-05 Verfahren zur herstellung eines arzneimittelkomplexes Expired - Lifetime DE69730352T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP14452296 1996-06-06
JP14452296 1996-06-06
PCT/JP1997/001915 WO1997046261A1 (fr) 1996-06-06 1997-06-05 Procede de fabrication de complexes medicamenteux

Publications (2)

Publication Number Publication Date
DE69730352D1 true DE69730352D1 (de) 2004-09-23
DE69730352T2 DE69730352T2 (de) 2005-09-08

Family

ID=15364300

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69730352T Expired - Lifetime DE69730352T2 (de) 1996-06-06 1997-06-05 Verfahren zur herstellung eines arzneimittelkomplexes

Country Status (16)

Country Link
US (1) US6291671B1 (de)
EP (1) EP0955064B1 (de)
JP (1) JP4137184B2 (de)
CN (1) CN1227034C (de)
AT (1) ATE273716T1 (de)
AU (1) AU723442B2 (de)
CA (1) CA2257233A1 (de)
DE (1) DE69730352T2 (de)
DK (1) DK0955064T3 (de)
EA (1) EA001897B1 (de)
ES (1) ES2229355T3 (de)
ID (1) ID17243A (de)
NO (1) NO323626B1 (de)
PT (1) PT955064E (de)
TW (1) TW409058B (de)
WO (1) WO1997046261A1 (de)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW527183B (en) 1996-06-06 2003-04-11 Daiichi Seiyaku Co Drug complex
AU3733399A (en) * 1998-05-22 1999-12-13 Daiichi Pharmaceutical Co., Ltd. Drug composites
KR20030031502A (ko) * 2000-06-29 2003-04-21 다이이찌 세이야꾸 가부시기가이샤 디디에스 화합물 및 그의 제조방법
US20040234497A1 (en) * 2001-05-04 2004-11-25 Yi Luo Hyaluronic acid containing bioconjugates:targeted delivery of anti-cancer drugs to cancer cells
US20030049253A1 (en) * 2001-08-08 2003-03-13 Li Frank Q. Polymeric conjugates for delivery of MHC-recognized epitopes via peptide vaccines
CA2483696A1 (en) * 2002-05-06 2003-11-20 University Of Utah Research Foundation Preblocking with non-ha gags increases effectiveness of ha conjugated anticancer agents
US7691830B2 (en) * 2005-02-17 2010-04-06 Clive Elson Method and composition for treatment of a mucosal tissue disorder
MX2007013725A (es) 2005-05-05 2008-04-09 Sensient Flavors Inc Produccion de beta-glucanos y mananos.
WO2007004675A1 (ja) * 2005-07-06 2007-01-11 Seikagaku Corporation 薬剤導入光架橋ヒアルロン酸誘導体ゲル
ITPD20050242A1 (it) 2005-08-03 2007-02-04 Fidia Farmaceutici Bioconiugati antitumorali dell'acido ialuronico o dei suoi derivati, ottenibili per coniugazione chimica diretta o indiretta, e loro impiego in campo farmaceutico
CN1973902B (zh) * 2006-12-12 2010-11-10 东北师范大学 以人参多糖为载体的抗肿瘤药物阿霉素复合物及制备方法
DK2576638T3 (da) 2010-05-25 2021-03-15 Syndevrx Inc Polymerkonjugerede metap2-inhibitorer og terapeutiske fremgangsmåder til anvendelse deraf
US9895449B2 (en) 2010-05-25 2018-02-20 Syndevrx, Inc. Polymer-conjugated MetAP2 inhibitors, and therapeutic methods of use thereof
MX364484B (es) 2012-10-11 2019-04-29 Daiichi Sankyo Co Ltd Conjugado de anticuerpo-fármaco.
ES2782248T3 (es) 2012-10-19 2020-09-11 Daiichi Sankyo Co Ltd Conjugado de anticuerpo y fármaco producido por la unión a través de un enlazador que tiene estructura hidrófila
US9173956B2 (en) 2013-04-10 2015-11-03 Syndevrx, Inc. METAP2 inhibitors and methods of treating obesity
WO2015071841A1 (en) 2013-11-12 2015-05-21 Druggability Technologies Holdings Limited Complexes of dabigatran and its derivatives, process for the preparation thereof and pharmaceutical compositions containing them
HRP20250673T1 (hr) 2013-12-25 2025-08-01 Daiichi Sankyo Company, Limited Postupak za proizvodnju konjugata anti-trop2 antitijelo-lijek
KR102314913B1 (ko) 2014-01-31 2021-10-19 다이이찌 산쿄 가부시키가이샤 항-her2 항체-약물 접합체
ES2754348T3 (es) 2014-04-10 2020-04-17 Daiichi Sankyo Co Ltd Conjugado de (anticuerpo anti-HER2)-fármaco
KR102186027B1 (ko) 2014-04-10 2020-12-03 다이이치 산쿄 유럽 게엠베하 항her3 항체-약물 콘주게이트
AU2016286898B2 (en) 2015-06-29 2022-12-08 Daiichi Sankyo Company, Limited Method for selectively manufacturing antibody-drug conjugate
ES2893749T3 (es) 2015-12-10 2022-02-10 Syndevrx Inc Derivados de fumagilol y polimorfos de los mismos
CA3008960C (en) 2016-01-11 2024-07-02 Syndevrx, Inc. TREATMENT OF TUMORS INDUCED BY METABOLIC DYSFUNCTION
KR20250040100A (ko) 2016-12-12 2025-03-21 다이이찌 산쿄 가부시키가이샤 항체-약물 콘주게이트와 면역 체크 포인트 저해제의 조합
CA3050668C (en) 2017-01-17 2023-08-15 Daiichi Sankyo Company, Limited Anti-gpr20 antibody and anti-gpr20 antibody-drug conjugate
TW202532106A (zh) 2017-05-15 2025-08-16 日商第一三共股份有限公司 抗體-藥物結合物之製造方法
KR102816741B1 (ko) 2017-08-31 2025-06-04 다이이찌 산쿄 가부시키가이샤 항체-약물 콘주게이트의 개량 제조 방법
JP7248578B2 (ja) 2017-08-31 2023-03-29 第一三共株式会社 抗体-薬物コンジュゲートの新規製造方法
HUE067382T2 (hu) 2018-05-18 2024-10-28 Daiichi Sankyo Co Ltd Anti-MUC1-exatecan antitest-hatóanyag konjugátum
WO2020022475A1 (ja) 2018-07-27 2020-01-30 第一三共株式会社 抗体-薬物コンジュゲートの薬物部位を認識する蛋白質
CN112805036A (zh) 2018-07-31 2021-05-14 第一三共株式会社 通过施用抗体-药物缀合物对转移性脑肿瘤的治疗
WO2020087077A1 (en) 2018-10-26 2020-04-30 Syndevrx,Inc. Biomarkers of metap2 inhibitors and applications thereof
US11634508B2 (en) 2019-07-10 2023-04-25 Cybrexa 2, Inc. Peptide conjugates of cytotoxins as therapeutics
CN114302744B (zh) 2019-07-10 2025-08-26 赛博克萨3公司 作为治疗剂的微管靶向剂的肽缀合物
US11806405B1 (en) 2021-07-19 2023-11-07 Zeno Management, Inc. Immunoconjugates and methods

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5746920A (en) * 1980-09-03 1982-03-17 Kyosei Seiyaku Kk Drug for digestive tract
GB2093697A (en) * 1980-09-03 1982-09-08 Kyosei Pharmaceutical Co Ltd Agent for alimentary canal
JPS59220197A (ja) * 1983-05-30 1984-12-11 Snow Brand Milk Prod Co Ltd 新規な含窒素多糖体およびその製造方法
JP2604930B2 (ja) * 1990-12-14 1997-04-30 株式会社ディ・ディ・エス研究所 ヒアルロン酸およびコンドロイチン誘導体
CA2059693C (en) * 1991-01-28 2003-08-19 Peter J. Kniskern Polysaccharide antigens from streptococcus pneumoniae
WO1992014759A1 (fr) 1991-02-21 1992-09-03 Drug Delivery System Institute, Ltd. Carboxymethylmannoglucane et derive
JP3359955B2 (ja) 1992-07-16 2002-12-24 第一製薬株式会社 抗腫瘍剤
WO1994019376A1 (fr) 1993-02-26 1994-09-01 Drug Delivery System Institute, Ltd. Derive de polysaccharide et vehicule de medicament
JPH0784481A (ja) 1993-06-26 1995-03-31 Ricoh Co Ltd 画像形成装置
SG50747A1 (en) 1995-08-02 1998-07-20 Tanabe Seiyaku Co Comptothecin derivatives
TW527183B (en) 1996-06-06 2003-04-11 Daiichi Seiyaku Co Drug complex
US6299881B1 (en) * 1997-03-24 2001-10-09 Henry M. Jackson Foundation For The Advancement Of Military Medicine Uronium salts for activating hydroxyls, carboxyls, and polysaccharides, and conjugate vaccines, immunogens, and other useful immunological reagents produced using uronium salts

Also Published As

Publication number Publication date
NO985667D0 (no) 1998-12-04
AU2978897A (en) 1998-01-05
CN1227500A (zh) 1999-09-01
WO1997046261A1 (fr) 1997-12-11
TW409058B (en) 2000-10-21
ES2229355T3 (es) 2005-04-16
EP0955064A4 (de) 2000-12-06
CA2257233A1 (en) 1997-12-11
NO323626B1 (no) 2007-06-18
DE69730352T2 (de) 2005-09-08
CN1227034C (zh) 2005-11-16
DK0955064T3 (da) 2004-12-06
ID17243A (id) 1997-12-11
EP0955064A1 (de) 1999-11-10
EA001897B1 (ru) 2001-10-22
EA199900002A1 (ru) 1999-08-26
PT955064E (pt) 2004-10-29
AU723442B2 (en) 2000-08-24
ATE273716T1 (de) 2004-09-15
US6291671B1 (en) 2001-09-18
NO985667L (no) 1999-02-04
EP0955064B1 (de) 2004-08-18
JP4137184B2 (ja) 2008-08-20

Similar Documents

Publication Publication Date Title
DE69730352D1 (de) Verfahren zur herstellung eines arzneimittelkomplexes
ATE121414T1 (de) Verfahren zur herstellung von erythromcin a-oxim oder eines salzes davon.
DE69900462D1 (de) Konjugate von dns und pns und verfahren zu deren herstellung
DE69011880D1 (de) Verfahren zur Herstellung von L-Aminosäuren durch Fermentation.
FI881496A7 (fi) Menetelmä aminohappojen valmistamiseksi tai uuttamiseksi lannasta
ATE359256T1 (de) Verfahren zur herstellung von (2r)-2- propyloktansäure
ATA342186A (de) Verfahren zur herstellung eines organischen carbonsaeureanhydrids
DE59001820D1 (de) Verfahren zur herstellung von indolcarbonsaeurederivaten.
DE60009836D1 (de) Verfahren zur herstellung von 5-hydroxy-3-oxo-pentansäure-derivaten
ES436565A1 (es) Un procedimiento para la preparacion de acidos acetamidope- nicilanicos.
DE68923534D1 (de) Verfahren zur Herstellung eines organischen Kristalls.
EP1336603A4 (de) Verfahren zur einführung von aminogruppen und verfahren zur synthese von aminosäuren
DE69520368D1 (de) Verfahren zur herstellung von 5-hydroxymethyl-thiazole
ATE189220T1 (de) Verfahren zur herstellung von 7-(3-amino- sowie 3-aminomethyl-1-pyrrolidinyl)-3-chinolon- carbonsäuren sowie -naphthyridoncarbonsäuren
ATE384067T1 (de) Verfahren zur herstellung von 3-cephemderivaten
RU93004665A (ru) Микробиологический способ гидроксилирования азот-гетероциклических-карбоновых кислот
DE68925951D1 (de) Chemisches Verfahren zur Herstellung des Antibiotikums L 17392 (Deglukoteicoplanin) und dessen Salze
DE3765370D1 (de) Verfahren zur herstellung eines o-naphtochinondiazidsulfonsaeureesters.
PT83837A (de) Verfahren zur herstellung von peptiden unter der verwendung von perchloraten
ATE128456T1 (de) Verfahren zur herstellung eines alpha-amino- alkohols.
ATE222887T1 (de) Verfahren zur herstellung von inorganischen salzen von optisch aktiven phenylglycin-derivaten
DE69926642D1 (de) Verfahren zur herstellung von n-geschützten azetidin-2-carbonsäuren
EP0226132A3 (de) Dipeptide mit C-terminalem Phosphinothricin, Verfahren zu ihrer Herstellung und ihre Verwendung zur Bekämpfung unerwünschten Pflanzenwuchses
DE58905083D1 (de) Verfahren zur herstellung von thiophenderivaten sowie dihydrothiophen-1-oxide.
ATE202334T1 (de) Verfahren zur herstellung von n omega- trifluoracetylierten basischen aminosäuren

Legal Events

Date Code Title Description
8364 No opposition during term of opposition